Determination of Epigenetic Markers of Acute Myeloblastic Leukemia in Elderly Patients

1. / Control Group Inclusion Criteria: * Age ≥ 60 years; * Scheduled for cardiac surgery involving sternotomy; * Normal blood count within the two months preceding sampling; * Affiliated with, or beneficiary of, a social security system; * Written informed consent to participate in the study. Exclusion Criteria: * Patients deemed unsuitable for sampling by the surgeon performing the procedure; * Patients under legal protection measures; * Patients under judicial supervision or deprived of liberty by judicial or administrative decision; * Presence of positive virological markers indicating active infection (hepatitis B, hepatitis C, or HIV). 2. / AML Group Inclusion Criteria: * Age ≥ 60 years; * Diagnosis of de novo AML or AML secondary to myelodysplastic syndrome, scheduled to receive azacitidine-based treatment; * Affiliated with, or beneficiary of, a social security system; * Written informed consent to participate in the study. Exclusion Criteria: * Diagnosis of a hematologic disease other than AML; * Clinical signs suggestive of active central nervous system leukemia, or presence of isolated extramedullary leukemia; * Previous treatment for AML other than hydroxyurea; * Severe comorbidities that could interfere with the study, as assessed by the principal investigator; * Presence of positive virological markers indicating active infection (hepatitis B, hepatitis C, or HIV); * Patients under legal protection; * Patients under judicial supervision or deprived of liberty by judicial or administrative decision.